On December 23, 2024, Robin Swartz, Chief Operating Officer and Chief Business Officer of Voyager Therapeutics Inc, sold 6,500 shares of the company, as reported in a SEC Filing. Following this transaction, the insider now owns 112,328 shares of the company.
Voyager Therapeutics Inc (VYGR, Financial) is a biotechnology company focused on developing gene therapies for severe neurological diseases. The company aims to address diseases such as Parkinson's disease, Huntington's disease, and other central nervous system disorders through innovative gene therapy solutions.
The insider transaction history for Voyager Therapeutics Inc indicates that there have been no insider buys over the past year, while there have been 10 insider sells during the same period. Over the past year, Robin Swartz has sold a total of 14,366 shares and has not purchased any shares.
As of the date of the recent transaction, shares of Voyager Therapeutics Inc were trading at $5.65 each, giving the stock a market cap of $322.844 million. The company's price-earnings ratio stands at 9.09, which is lower than the industry median of 25.77 but higher than the company's historical median price-earnings ratio.
With a trading price of $5.65 and a GF Value of $5.86, Voyager Therapeutics Inc has a price-to-GF-Value ratio of 0.96, indicating that the stock is fairly valued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples, a GuruFocus adjustment factor, and future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
